Diarylaniline derivatives as a distinct class of HIV-1 non-nucleoside reverse transcriptase inhibitors

Journal of Medicinal Chemistry

Volumn 53, Issue 13, 2010, Pages 4906-4916

  Qin, Bingjie ^a   Jiang, Xingkai ^a   Lu, Hong ^c   Tian, Xingtao ^a   Barbault, Florent ^d   Huang, Li ^e   Qian, Keduo ^b   Chen, Chin Ho ^e   Huang, Rong ^b   Jiang, Shibo ^c   Lee, Kuo Hsiung ^b   Xie, Lan ^a  

^a BEIJING INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY   (China)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c NEW YORK BLOOD CENTER   (United States)

^d UNIVERSITÉ PARIS DIDEROT   (France)

^e DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,5 DIARYLBENZENE 1,2 DIAMINE DERIVATIVE; 5 (4'' BROMO 2'',6'' DIMETHYLPHENOXY) N1 (4' CYANOPHENYL) 4 NITROBENZENE 1,2 DIAMINE; 5 (4'' CYANO 2'',6'' DIMETHYLPHENOXY) N (4' CYANOPHENYL) 2,4 DINITROANILINE; 5 (4'' CYANO 2'',6'' DIMETHYLPHENOXY) N1 (4' CYANOPHENYL) 4 NITROBENZENE 1,2 DIAMINE; 5 (4'' CYANO 2'',6'' DIMETHYLPHENOXY) N1 (4' CYANOPHENYL)BENZENE 1,2,4 TRIAMINE; ANILINE DERIVATIVE; DIAMINE DERIVATIVE; ETRAVIRINE; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RILPIVIRINE; UNCLASSIFIED DRUG; ZIDOVUDINE;

ANTIVIRAL RESISTANCE; ARTICLE; CONTROLLED STUDY; DRUG BINDING SITE; DRUG DESIGN; DRUG MECHANISM; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; MOLECULAR MODEL; NONHUMAN; STRUCTURE ACTIVITY RELATION; VIRUS STRAIN; WILD TYPE;

ANILINE COMPOUNDS; HIV INFECTIONS; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; HYDROGEN BONDING; MAGNETIC RESONANCE SPECTROSCOPY; MODELS, MOLECULAR; REVERSE TRANSCRIPTASE INHIBITORS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 77954338696     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm1002952     Document Type: Article

References (43)

1. Tantillo, C.; Ding, J. P.; Jacobo-Molina, A.; Nanni, R. G.; Boyer, P. L.; Hughes, S. H.; Pauwels, R.; Andries, K.; Janssen, P. A. J.; Arnold, E. Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase: implications for mechanisms of drug inhibition and resistance J. Mol. Biol. 1994, 243, 369-387
2. Pauwels, R. New non-nucleoside reverse transcriptase inhibitors (NNRTIs) in development for the treatment of HIV infections Curr. Opin. Pharmacol. 2004, 4, 437-446
3. Andries, K.; Azijn, H.; Thielemans, T.; Ludovici, D.; Kukla, M.; Heeres, J.; Janssen, P.; De Corte, B.; Vingerhoets, J.; Pauwels, R.; de Béthuneet, M. P. TMC125, a novel next- generation nonnucleoside reverse transcriptase inhibitor active against non-nucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1 Antimicrob. Agents Chemother. 2004, 48, 4680-4686
4. Janssen, P. A. J.; Lewi, P. J.; Arnold, E.; Daeyaert, F.; de Jonge, M.; Heeres, J.; Koymans, L.; Vinkers, M.; Guillemont, J.; Pasquier, E.; Kukla, M.; Ludovici, D.; Andries, K.; de Bethune, M. P.; Pauwels, R.; Das, K.; Clark, A. D.; Frenkel, Y. V.; Hughes, S. H.; Medaer, B.; De Knaep, F.; Bohets, H.; De Clerck, F.; Lampo, A.; Williams, P.; Stoffels, P. In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1 E)-2- cyanoethenyl]-2,6-dimethylphenyl] amino]-2-pyrimidinyl]amino]benzonitrile (R278474, rilpivirine) J. Med. Chem. 2005, 48, 1901-1909
5. De Clercq, E. Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV Int. J. Antimicrob. Agents 2009, 33, 307-320
6. Tucker, T. J.; Sisko, J. T.; Tynebor, R. M.; Williams, T. M.; Felock, P. J.; Flynn, J. A.; Lai, M. T.; Liang, Y. X.; Gaughey, G. M.; Liu, M. Q.; Miller, M.; Moyer, G.; Munshi, V.; Perlow- Poehnelt, R.; Prasad, S.; Reid, J. C.; Sanchez, R.; Torrent, M.; Vacca, J. P.; Wan, B. L.; Yan, Y. W. Discovery of 3-{5-[(6-Amino-1 H -pyrazolo [3,4- b ]pyridine-3-yl)methoxy]-2- chlorophenoxy}-5-chlorobenzonitrile (MK-4965): a potent, orally bioavailable HIV-1 non-nucleoside reverse transcriptase inhibitor with improved potency against key mutant viruses J. Med. Chem. 2008, 51, 6503-6511
7. Romines, K. R.; Freeman, G. A.; Schaller, L. T.; Cowan, J. R.; Gonzales, S. S.; Tidwell, J. H.; Andrews, C. W.; Stammers, D. K.; Hazen, R. J.; Ferris, R. G.; Short, S. A.; Chan, J. H.; Boone, L. R. Structure-activity relationship studies of novel benzophenones leading to the discovery of a potent, next generation HIV non-nucleoside reverse transcriptase inhibitor J. Med. Chem. 2006, 49, 727-739
8. Himmel, D. M.; Das, K.; Clark, A. D.; Hughes, S. H.; Benjahad, A.; Oumouch, S.; Guillemont, J.; Coupa, S.; Poncelet, A.; Csoka, I.; Meyer, C.; Andries, K.; Nguyen, C. H.; Grierson, D. S.; Arnold, E. Crystal structures for HIV-1 reverse transcriptase in complexes with three pyridinone derivatives: a new class of non-nucleoside inhibitors effective against a broad range of drug-resistant strains J. Med. Chem. 2005, 48, 7582-7591
9. Das, K.; Lewi, P. J.; Hughes, S. H.; Arnold, E. Crystallography and the design of anti-AIDS drugs: conformational flexibility and positional adaptability are important in the design of non-nucleoside HIV-1 reverse transcriptase inhibitors Prog. Biophys. Mol. Biol. 2005, 88, 209-231
10. De Corte, B. L. From 4,5,6,7-Tetrahydro-5-methylimidazo[4,5,1- jk ](1,4)benzodiazepin- 2(1 H)-one (TIBO) to Etravirine (TMC125): Fifteen Years of Research on Non-Nucleoside Inhibitors of HIV-1 Reverse Transcriptase J. Med. Chem. 2005, 48, 1689-1696
11. Das, K.; Clark, A. D., Jr.; Lewi, P. J.; Heeres, J.; De Jonge, M. R.; Koymans, L. M.; Vinkers, H. M.; Daeyaert, F.; Ludovici, D. W.; Kukla, M. J.; De Corte, B.; Kavash, R. W.; Ho, C. Y.; Ye, H.; Lichtenstein, M. A.; Andries, K.; Pauwels, R.; De Béthune, M.-P.; Boyer, P. L.; Clark, P.; Hughes, S. H.; Janssen, P. A.; Arnold, E. Roles of conformational and positional adaptability in structure based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants J. Med. Chem. 2004, 47, 2550-2560
12. Das, K.; Bauman, J. D.; Clark, A. D.; Frenkel, Y. V.; Lewi, P. J.; Shatkin, A. J.; Hughes, S. H.; Arnold, E. High-resolution structures of HIV-1 reverse transcriptase/TMC278 complexes: strategic flexibility explains potency against resistance mutations Proc. Natl. Acad. Sci. U.S.A. 2008, 105, 1466-1471
13. Heeres, J.; de Jonge, M.; Koymans, L. M. H.; Daeyaert, F. F. D.; Vinkers, M.; Van Aken, K. J. A.; Arnold, E.; Das, K.; Kilonda, A.; Hoornaert, G. J.; Compernolle, F.; Cegla, M.; Azzam, R. A.; Andries, K.; de Béthune, M.-P.; Azijn, H.; Pauwels, R.; Lewi, P. J.; Janssen, P. A. J. Design, synthesis, and SAR of a novel pyrazinone series with non-nucleoside HIV-1 reverse transcriptase inhibitory activity J. Med. Chem. 2005, 48, 1910-1918
14. Zeevaart, J. G.; Wang, L.; Thakur, V. V.; Leung, C. S.; Tirado-Rives, J.; Bailey, C. M.; Domaoal, R. A.; Anderson, K. S.; Jorgensen, W. L. Optimization of azoles as anti-human immunodeficiency virus agents guided by free-energy calculations J. Am. Chem. Soc. 2008, 130, 9492-9499
15. Sweeney, Z. K.; Dunn, J. P.; Li, Y.; Heilek, G.; Dunten, P.; Elworthy, T. R.; Han, X. C.; Harris, S. F.; Hirschfeld, D. R.; Hogg, J. H.; Huber, W.; Kaiser, A. C.; Kertesz, D. J.; Kim, W.; Mirzadegan, T.; Roepel, M. G.; Saito, Y. D.; Silva, T. M. P. C.; Swallow, S.; Tracy, J. L.; Villasenor, A.; Vora, H.; Zhou, A. S.; Klumpp, K. Discovery and optimization of pyridazinone non-nucleoside inhibitors of HIV-1 reverse transcriptase Bioorg. Med. Chem. Lett. 2008, 18, 4352-4354
16. Frlan, R.; Kikelj, D. Recent progress in diaryl ether synthesis Synthesis 2006, 14, 2271-2285
17. Li, F.; Wang, Q. R.; Ding, Z. B.; Tao, F. G. Microwave-assisted synthesis of diaryl ethers without catalyst Org. Lett. 2003, 5, 2169-2171
18. Piersanti, G.; Giorgi, L.; Bartoccini, F.; Tarzia, G.; Minetti, P.; Gallo, G.; Giorgi, F.; Castorina, M.; Ghirardi, O.; Carminati, P. Synthesis of benzo[1,2- d;3,4- d ]diimidazole and 1 H -pyrazolo[4,3- b ]pyridine as putative A2A receptor antagonists Org. Biomol. Chem. 2007, 5, 2567-2571
19. Tian, X. T.; Qin, B. J.; Lu, H.; Lai, W. H.; Jiang, S.; Lee, K. H.; Chen, C. H.; Xie, L. Discovery of diarylpyridine derivatives as novel non-nucleoside HIV-1 reverse transcriptase inhibitors Bioorg. Med. Chem. Lett. 2009, 19, 5482-5485
20. Gohlke, H.; Kiel, C.; Case, D. A. Insights into protein-protein binding by binding free energy calculation and free energy decomposition for the Ras-Raf and Ras-RalGDS complexes J. Mol. Biol. 2003, 330, 891-913
21. Obiol-Pardo, C.; Rubio-Martinez, J. Comparative evaluation of MMPBSA and XSCORE to compute binding free energy in XIAP-peptide complexes J. Chem. Inf. Model. 2007, 47, 134-142
22. Guimaraes, C. R.; Cardozo, M. MM-GB/SA rescoring of docking poses in structure-based lead optimization J. Chem. Inf. Model. 2008, 48, 958-970
23. Ludovici, D. W.; De Corte, B. L.; Kukla, M. J.; Ye, H.; Ho, C. Y.; Lichtenstein, M. A.; Kavash, R. W.; Andries, K.; de Bethune, M. P.; Azijn, H.; Pauwels, R.; Lewi, P. J.; Heeres, J.; Koymans, L. M. H.; de Jonge, M. R.; Van Aken, K. J. A.; Daeyaert, F. F. D.; Das, K.; Arnold, E.; Janssen, P. A. J. Evolution of anti-HIV drug candidates. part 3: diarylpyrimidine (DAPY) analogues Bioorg. Med. Chem. Lett. 2001, 11, 2235-2239 (Pubitemid 32781673)
24. Mordant, C.; Schmitt, B.; Pasquier, E.; Demestre, C.; Queguiner, L.; Masungi, C.; Peeters, A.; Smeulders, L.; Bettens, E.; Hertogs, K.; Heeres, J.; Lewi, P.; Guillemont, J. Synthesis of novel diarylpyrimidine analogues of TMC278 and their antiviral activity against HIV-1 wild-type and mutant strains Eur. J. Med. Chem. 2007, 42, 567-579
25. Zhao, Q.; Ma, L.; Jiang, S.; Lu, H.; Liu, S.; He, Y.; Strick, N.; Neamati, N.; Debnath, A. K. Identification of N -phenyl- N ′-(2,2,6,6- tetramethylpiperidin-4-yl)-oxalamides as a new class of HIV-1 entry inhibitors that prevent gp120 binding to CD4 Virology 2005, 339, 213-225
26. Chou, T. C.; Talalay, P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors Adv. Enzyme Regul. 1984, 22, 27-55
27. Dupnik, K. M.; Gonzales, M. J.; Shafer, R. W. Most multidrug-resistant HIV-1 reverse transcriptase clones in plasma encode functional reverse transcriptase enzymes Antivir. Ther. 2001, 6, 41-46
28. SYBYL 7.0; Tripos Inc.: 1699 South Hanley Road, St Louis, MO 63144.
29. Case, D.; Darden, T.; Cheatham, T.; Simmerling, C.; Wang, J.; Duke, R.; Luo, R.; Merz, K.; Pearlman, D.; Crowley, M.; Walker, R.; Zhang, W.; Wang, B.; Hayik, S.; Roitberg, A.; Seabra, G.; Wong, K.; Paesani, F.; Wu, X.; Brozell, S.; Tsui, V.; Gohlke, H.; Yang, L.; Tan, C.; Mongan, J.; Hornak, V.; Cui, G.; Beroza, P.; Mathews, D.; Schafmeister, C.; Ross, W.; Kollman, P. AMBER, 9.0; University of California: San Francisco, 2006.
30. Dewar, M.; Zoebisch, E.; Healy, E.; Stewart, J. AM1: A new general purpose quantum mechanical molecular model J. Am. Chem. Soc. 1985, 107, 3902-3909
31. Jakalian, A.; Bush, B. L.; Jack, D. B.; Bayly, C. I. Fast, efficient generation of high-quality atomic charges. AM1-BCC model: I. Method J. Comput. Chem. 2000, 21, 132-146
32. Jakalian, A.; Jack, D. B.; Bayly, C. I. Fast, efficient generation of high-quality atomic charges. AM1-BCC model: II. Parameterization and validation J. Comput. Chem. 2002, 23, 1623-1641
33. Wang, J.; Wolf, R. M.; Caldwell, J. W.; Kollman, P. A.; Case, D. A. Development and testing of a general amber force field J. Comput. Chem. 2004, 25, 1157-1174
34. Duan, Y.; Wu, C.; Chowdhury, S.; Lee, M. C.; Xiong, G.; Zhang, W.; Yang, R.; Cieplak, P.; Luo, R.; Lee, T.; Caldwell, J.; Wang, J.; Kollman, P. A point-charge force field for molecular mechanics simulations of proteins based on condensed-phase quantum mechanical calculations J. Comput. Chem. 2003, 24, 1999-2012
35. Beroza, P.; Case, D. Calculations of proton-binding thermodynamics in proteins Methods Enzymol. 1998, 295, 170-189
36. Cramer, C. J.; Truhlar, D. G. Implicit solvation models: equilibria, structure, spectra, and dynamics Chem. Rev. 1999, 99, 2161-2200
37. Gilson, M. K. Theory of electrostatic interactions in macromolecules Curr. Opin. Struct. Biol. 1995, 5, 216-223
38. Madura, J. D.; Davis, M. E.; Gilson, M. K.; Wade, R. C.; Luty, B. A.; Mc Cammon, J. A. Biological applications of electrostatic calculations and brownian dynamics simulations Rev. Comput. Chem. 1994, 5, 229-267
39. Kollman, P. A.; Massova, I.; Reyes, C.; Kuhn, B.; Huo, S.; Chong, L.; Lee, M.; Lee, T.; Duan, Y.; Wang, W.; Donini, O.; Cieplak, P.; Srinivasan, J.; Case, D. A.; Cheatham, T. E., III. Calculating structures and free energies of complex molecules: combining molecular mechanics and continuum models Acc. Chem. Res. 2000, 33, 889-897
40. Wang, J.; Morin, P.; Wang, W.; Kollman, P. A. Use of MM-PBSA in reproducing the binding free energies to HIV-1 RT of TIBO derivatives and predicting the binding mode to HIV-1 RT of efavirenz by docking and MM-PBSA J. Am. Chem. Soc. 2001, 123, 5221-5230
41. Wang, W.; Kollman, P. A. Computational study of protein specificity: the molecular basis of HIV-1 protease drug resistance Proc. Natl. Acad. Sci. U.S.A. 2001, 98, 14937-14942
42. Luo, Y.; Barbault, F.; Gourmala, C.; Zhang, Y.; Maurel, F.; Hu, Y.; Fan, B. Cellular interaction through LewisX cluster: theoretical studies J. Mol. Model. 2008, 14, 901-910
43. Humphrey, W.; Dalke, A.; Schulten, K. VMD-visual molecular dynamics J. Mol. Graphics 1996, 14, 33-38